Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Atezolizumab is effective and well tolerated in pretreated advanced/metastatic non–small-cell lung cancer (NSCLC). We examined atezolizumab’s efficacy and safety in 64 Japanese patients with NSCLC in the same setting via a subanalysis of the phase 3 OAK study. Atezolizumab improved overall survival versus docetaxel and was generally well tolerated, thus offering a potential NSCLC treatment for Japanese patients.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2GNnUto
via IFTTT